- STAT+: Enliven Therapeutics’ leukemia drug shows promise in new studyA targeted drug from Enliven Therapeutics induced molecular responses in nearly half of patients with advanced leukemia, new data show.STAT · 1mo ago↗ source
- STAT+: ‘Synthetic lethality’ could trigger another round of biotech M&AProving out a "synthetic lethality" approach can help treat cancer will take a lot more work. It also might trigger some creative deal-making.STAT · 1mo ago↗ source
- HHS responds coolly to paper on alcohol riskSoda and liver cancer, scientists conflicted on a new NIH proposal, and more health news from Morning RoundsSTAT · 1mo ago↗ source